Established a “Placenta based Therapy for Degenerative Diseases”
(PTDD) platform that can newly manufacture and utilize placenta,
which was medical waste removed after childbirth, as a biological product

Isolation and culture of placental-derived stem cells from the placental
tissues extracted after childbirth, as well as the extraction and utilization
of various physiologically active substances in the placenta, are core technologies
based on placental preparations, and are the key to developing a new concept of treatment
for degenerative and intractable diseases.

It is a representative brand of mesenchymal stem cells with
excellent proliferative, multipotential and immunosuppressive
ability for placental-specific stem cells, isolated and cultured at high
purity from the chorionic valve of high-quality normal placental tissues.

This is a special brand that represents the next generation
of functionally enhanced stem cells with a non-viral-based
gene delivery system that optimized the expression of the
core genes that regulate regeneration and efficacy specifically
for each intractable and degenerative disease based on UNIPla,
a representative brand of placental stem cells, a priming system,
and an epigenetic regulation system.